

AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph starting on line 10 of page 1 as follows:

This application is a continuation-in-part of US application serial no. 09/696,668, now issued U.S. Patent 6,617,102, filed 25 October 2000, which is a continuation-in-part of US application serial no. 09/427,154, now issued U.S. Patent 6,589,725, filed 25 October 1999.

Please amend the paragraph starting on line 25 of page 14 as follows:

In a preferred embodiment, the present invention provides antisense oligonucleotides which find use as antagonists of TaHo activity. In a preferred embodiment, such antisense oligonucleotides are directed to the region in a TaHo nucleic acid intervening between the region encoding the SAM domain and the region encoding the PARP domain. Particularly preferred are antisense oligonucleotides having a nucleic acids sequence complementary to the nucleic acid sequence GTGGAACAGAGGGTGCTTCC (SEQ ID NO:7). This is a preferred sequence for specific antisense targeting of nucleic acid. As will be appreciated by those in the art, other TaHo nucleic acid sequence fragments that differ significantly from the sequence of tankyrase may be of use in the specific antisense targeting of TaHo. Alternatively, TaHo nucleic acid sequence fragments having high identity to tankyrase nucleic acid sequence fragments may be used to target both tankyrase and TaHo by antisense oligonucleotides.